Showing results (61-70 of 74) with videos related to
Sort By:
Pageof 8
Annals of the American Thoracic Society|August 16, 2019
Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical StabilityLindsay J Caverly, Junnan Lu, Lisa A Carmody, et al.American Journal of Respiratory and Critical Care Medicine|September 1, 2021
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation TreatmentChristopher H Goss, Sonya L Heltshe, Natalie E West, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2019
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung InfectionsValerie J Waters, Timothy J Kidd, Rafael Canton, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 3, 2019
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic reviewRanjani Somayaji, Michael D Parkins, Anand Shah, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 18, 2022
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbationsLaura S Gold, Ryan N Hansen, Donald L Patrick, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 2, 2017
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary ExacerbationsNatalie E West, Valeria V Beckett, Raksha Jain, et al.Proceedings of the National Academy of Sciences of the United States of America|March 28, 2012
Decade-long bacterial community dynamics in cystic fibrosis airwaysJiangchao Zhao, Patrick D Schloss, Linda M Kalikin, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 8, 2016
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patientsPatrick A Flume, Donald R VanDevanter, Elizabeth E Morgan, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2015
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsJ Stuart Elborn, David E Geller, Douglas Conrad, et al.Annals of the American Thoracic Society|November 14, 2023
Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary ExacerbationsChristina S Thornton, Lindsay J Caverly, Linda M Kalikin, et al.Pageof 8